Protein kinase B
Insulin and PKB
PKB is phosphorylated at two sites and therefore activated by 3-phosphoinositide dependent protein kinase (PDK). PDK is a kinase associated with the plasma membrane (PDK binds PIP3 via its PH domain) and activated by Protein Kinase C (PKC) as a result of the PI3K pathway. Although the exact mechanism is unknown, this pathway is associated with the translocation of GLUT4 transporters to the plasma membrane, enabling uptake of glucose into the cell.
PKB phosphorylates TSC2 (Tuberous sclerosis complex 2) which therefore becomes inactivated. This is a GTPase Activating Protein which phosphorylates and inactivates Rheb – a small G protein. This means that phosphorylation of TSC2 by PKB allows activation of Rheb and the completion of the mTor pathway leading to increased transcription by activation of p70 ribosomal protein S6 kinase (S6K1). PKB therefore increases protein synthesis.
PKB also phosphorylates glycogen synthase kinase 3 (GSK3) which then becomes inactivated. This means GSK3 is no longer available to inactivate glycogen synthase which incorporates UDP-glucose into a chain of glycogen for storage. PKB therefore increases glycogen synthesis.
Effect on lipolysis
PKB decreases lipolysis by activation of phosphodiesterase 3B (PDE3B). This enzyme is responsible for the breakdown of cAMP to 5’AMP resulting in less activation of protein kinase A (PKA). PKA usually phosphorylates (and activates) Hormone Sensitive Lipase (HSL) which converts triacylglycerides into free fatty acids and glycerol. Since there is less activation of HSL with less PKA, lipolysis is reduced. This effect is further established by reduced phosphorylation of perilipin by PKA. This is a protein bound to the surface of fat droplets in adipocytes which prevent lipolysis by blocking HSL access.
Implications in disease
There is concern over the expression or mutation of the PI3K-Akt pathway due to its involvement in other important cellular processes such as cell proliferation, survival and growth. * In many tumour cells, there is hyperactivation of this pathway, suggesting inhibitors of this pathway could help prevent growth of tumour cells and therefore contribute towards the treatment of human cancer.
As well as its role in diabetes and cancer, dysfunctional PKB regulation is now implied in some neurodegenerative disorders such as Huntington’s disease, Alzheimer’s disease and Schizophrenia due to its role in the growth and protection of neuronal cells.